FGF‐21 levels in DS patients versus normal controls and the FGF‐21 level in DS patients with different clinical features including intellectual development, seizure frequency, ASDs, and the types of SCN1A mutations were then compared. This evidence concerns the gene SCN1A and Dravet syndrome.